BD Committed To Global Health; Mitigating Blood Culture Vial Supplier Issue With FDA Collaboration, Rapid Production, And Restarting Glass Vial Production; Manual Allocation To Prioritize Clinical Needs; No Material Financial Impact Expected

7/10/24 12:15:07 PM ET

Medical/Dental Instruments

Health Care

Get the next $BDX alert in real time by email

Get the next $BDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDX

Date	Price Target	Rating	Analyst
10/1/2024	$255.00 → $275.00	Neutral → Buy	Citigroup
5/30/2024	$274.00	Buy	Goldman
7/24/2023	$305.00	Mkt Perform → Outperform	Raymond James
5/30/2023	$295.00	Overweight	Morgan Stanley
5/5/2023	$260.00 → $290.00	Neutral → Overweight	Piper Sandler
4/12/2023	$304.00	Sector Weight → Overweight	KeyBanc Capital Markets
1/3/2023	$250.00 → $290.00	Neutral → Buy	BofA Securities
12/12/2022	$221.00 → $250.00	Sell → Neutral	Citigroup

More analyst ratings

$BDX
Press Releases

Fastest customizable press release news feed in the world

First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
BROWNSVILLE, Texas, Nov. 20, 2024 /PRNewswire/ -- A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities has officially launched in Texas. HPV is the cause of virtually all cervical cancers. The study is being conducted at Su Clinica, a Federally Qualified Health Center (FQHC) with locations in Brownsville, Harlingen, Raymondville, and Santa Rosa, Texas, together with researchers at The University of Texas MD Anderson Cancer Center. This study will evaluate the implementatio
11/20/24 2:15:00 PM ET
$BDX
Medical/Dental Instruments
Health Care
BD to Present at the 7th Annual Evercore ISI HealthCONx Conference
FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports t
11/19/24 4:15:00 PM ET
$BDX
Medical/Dental Instruments
Health Care
BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
11/7/24 6:30:00 AM ET
$BDX
Medical/Dental Instruments
Health Care

Revelyst Announces Chief Supply Chain Officer
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
4/23/24 7:00:00 AM ET
$BDX
$EMBC
$VSTO
Medical/Dental Instruments
Health Care
Ordnance And Accessories
Industrials
Zeus Names New Chief Executive Officer
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
3/14/24 1:00:00 PM ET
$BDX
Medical/Dental Instruments
Health Care
Zeus Names New Chief Executive Officer
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
3/14/24 1:00:00 PM ET
$BDX
Medical/Dental Instruments
Health Care

$BDX
Financials

Live finance-specific insights

BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
11/7/24 6:30:00 AM ET
$BDX
Medical/Dental Instruments
Health Care
BD Board Increases Dividend for 53rd Consecutive Year
FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024. The indicated annual dividend rate for fiscal year 2025 is $4.16 per share. "This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
11/7/24 6:25:00 AM ET
$BDX
Medical/Dental Instruments
Health Care
BD Completes Acquisition of Critical Care from Edwards Lifesciences
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision toolsCombination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilitiesBusiness renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segmentKatie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide presidentFRANKLIN LAKES, N.J., Sept. 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technolo
9/3/24 4:30:00 PM ET
$BDX
Medical/Dental Instruments
Health Care

BD Committed To Global Health; Mitigating Blood Culture Vial Supplier Issue With FDA Collaboration, Rapid Production, And Restarting Glass Vial Production; Manual Allocation To Prioritize Clinical Needs; No Material Financial Impact Expected

Chat with this insight

Recent Analyst Ratings for $BDX

$BDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

$BDX SEC Filings

Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$BDX Press Releases

Fastest customizable press release news feed in the world

First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities

BD to Present at the 7th Annual Evercore ISI HealthCONx Conference

BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

$BDX Leadership Updates

Live Leadership Updates

Revelyst Announces Chief Supply Chain Officer

Zeus Names New Chief Executive Officer

Zeus Names New Chief Executive Officer

$BDX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Jones Christopher Ian Montague

SEC Form 4 filed by Director Byington Carrie L

EVP & Chief Financial Officer Delorefice Christopher covered exercise/tax liability with 466 shares, decreasing direct ownership by 4% to 12,792 units (SEC Form 4)

$BDX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

$BDX Market Insights

Live Market Insights

$BDX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BD, Quest Diagnostics Partner To Develop Companion Diagnostics For Cancer, Other Diseases

Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

Becton Dickinson upgraded by Citigroup with a new price target

Goldman initiated coverage on Becton Dickinson with a new price target

Becton Dickinson upgraded by Raymond James with a new price target

$BDX Financials

Live finance-specific insights

BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

BD Board Increases Dividend for 53rd Consecutive Year

BD Completes Acquisition of Critical Care from Edwards Lifesciences

Recent Analyst Ratings for
$BDX

$BDX
Large Ownership Changes

$BDX
SEC Filings

$BDX
Press Releases

$BDX
Leadership Updates

$BDX
Insider Trading

$BDX
FDA approvals

$BDX
Market Insights

$BDX
Analyst Ratings

$BDX
Financials